Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically …
Over the last 12 months, insiders at Lixte Biotechnology Holdings, Inc. have bought $0 and sold $0 worth of Lixte Biotechnology Holdings, Inc. stock.
On average, over the past 5 years, insiders at Lixte Biotechnology Holdings, Inc. have bought $808,177 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,527 shares for transaction amount of $13,873 was made by Bernards Rene (director) on 2023‑10‑03.
2023-10-03 | director | 5,527 0.2398% | $2.51 | $13,873 | -13.14% | |||
2023-10-03 | President and CEO | 10,000 0.484% | $2.80 | $28,000 | -13.14% | |||
2023-10-02 | director | 4,473 0.1771% | $2.29 | $10,243 | -3.44% | |||
2022-12-30 | director | 10,000 0.0609% | $0.49 | $4,900 | +2.16% | |||
2022-12-15 | director | 15,000 0.0893% | $0.51 | $7,650 | -3.87% | |||
2022-12-12 | director | 10,000 0.0632% | $0.61 | $6,100 | -14.60% | |||
2022-12-09 | Vice President and COO | 1,112 0.0071% | $0.63 | $701 | -16.14% | |||
2022-11-22 | Vice President and COO | 2,484 0.0154% | $0.56 | $1,391 | -4.40% | |||
2022-11-21 | Vice President and COO | 1,457 0.0092% | $0.56 | $816 | -1.89% | |||
2022-11-21 | director | 5,000 0.0325% | $0.58 | $2,876 | -1.89% | |||
2022-11-18 | Vice President and COO | 16,207 0.0994% | $0.56 | $9,125 | -5.00% | |||
2022-11-17 | Vice President and COO | 4,852 0.0307% | $0.54 | $2,619 | +2.22% | |||
2022-11-14 | director | 52,500 0.3141% | $0.53 | $27,825 | -1.43% | |||
2020-11-30 | President and CEO | 21,100 0.0394% | $4.75 | $100,225 | -24.01% | |||
2020-11-30 | 10 percent owner | 52,632 0.0984% | $4.75 | $250,002 | -24.01% | |||
2020-11-30 | 10 percent owner | 105,264 0.1968% | $4.75 | $500,004 | -24.01% | |||
2020-11-30 | director | 52,632 0.0984% | $4.75 | $250,002 | -24.01% | |||
2020-11-30 | director | 21,053 0.0394% | $4.75 | $100,002 | -24.01% | |||
2020-11-30 | director | 21,053 0.0394% | $4.75 | $100,002 | -24.01% | |||
2020-11-30 | 10 percent owner | 42,105 0.0787% | $4.75 | $199,999 | -24.01% |
Riggs Arthur | 10 percent owner | 6110000 271.6413% | $1.57 | 3 | 0 | |
Kovach John S | President and CEO | 1540183 68.4742% | $1.57 | 1 | 0 | <0.0001% |
GREENBERG ROBERT | 10 percent owner | 994299 44.205% | $1.57 | 1 | 0 | <0.0001% |
Schwartzberg Gil | 10 percent owner | 247775 11.0157% | $1.57 | 3 | 0 | <0.0001% |
Yen Yun | director | 52632 2.3399% | $1.57 | 1 | 0 | <0.0001% |